

Table S1 Clinical and ultrasound characteristics of donor livers

Characteristics	Total (n=88)	Non-steatosis (n=44)	Steatosis (n=44)			P value
			Mild (n=30)	Moderate (n=9)	Severe (n=5)	
Cause of death						0.105
Trauma	34 (38.6)	20 (45.5)	12 (40.0)	2 (22.2)	0	
Cerebrovascular	49 (55.7)	20 (45.5)	17 (56.7)	7 (77.8)	5 (100.0)	
Hypoxic ischemic encephalopathy	5 (5.7)	4 (9.1)	1 (3.3)	0	0	
Hypertension	32 (36.4)	10 (22.7)	12 (40.0)	6 (66.7)	4 (80.0)	0.015
Hepatitis						0.059
Non-hepatitis	75 (85.2)	34 (77.3)	29 (96.7)	7 (77.8)	5 (100.0)	
HBV	9 (10.2)	6 (13.6)	1 (3.3)	2 (22.2)	0	
HCV	4 (4.5)	4 (9.1)	0	0	0	
Weight*, kg	64.08±10.32	61.85±7.86	64.53±11.28	65.56±10.74	78.40±13.43	0.042
Height, cm	168.00 (164.25–170.00)	169.00 (165.00–170.00)	165.00 (160.00–170.00)	170.00 (165.00–170.00)	170.00 (170.00–175.00)	0.725
Diameter of the portal vein, cm	1.09±0.16	1.10±0.17	1.08±0.15	1.04±0.17	1.15±0.08	0.634
PSV, cm/s	52.05 (37.70–77.32)	53.95 (37.05–77.30)	51.20 (40.00–82.32)	47.40 (42.60–51.60)	55.10 (40.00–77.40)	0.838
EDV, cm/s	19.85 (14.00–31.00)	19.80 (13.70–30.70)	21.25 (15.03–34.57)	21.00 (15.40–24.50)	19.40 (14.00–31.00)	0.881
Na ⁺ , mmol/L	151.31±9.85	152.14±10.69	150.07±9.93	153.44±7.40	147.60±3.21	0.433
K ⁺ , mmol/L	4.04 (3.49–4.46)	4.04 (3.59–4.40)	4.08 (3.54–4.56)	3.98 (3.35–4.30)	3.53 (3.51–4.44)	0.815
ALT, U/L	27.50 (20.00–59.25)	27.50 (19.00–54.25)	23.50 (17.75–54.00)	40.00 (32.00–129.00)	89.00 (24.00–208.00)	0.646
AST, U/L	59.50 (29.75–94.25)	58.50 (27.75–83.25)	48.00 (29.25–97.00)	90.00 (68.00–380.00)	95.00 (88.00–573.00)	0.309
Total bilirubin, µmol/L	24.05 (13.30–46.43)	23.25 (13.30–34.55)	25.65 (12.55–47.62)	34.00 (14.50–47.10)	23.10 (21.80–45.60)	0.518
Albumin, g/L	37.75 (34.20–42.47)	37.75 (35.18–39.73)	35.80 (33.65–42.80)	38.90 (36.30–51.00)	43.40 (38.70–43.60)	0.435
Leukocyte count, 10 ⁹ /L	10.28 (7.40–13.97)	10.34 (7.14–13.89)	10.26 (7.90–13.59)	11.17 (7.06–14.94)	9.75 (6.29–14.16)	0.723
Platelet*, 10 ⁹ /L	102.50 (64.00–156.00)	134.00 (74.00–190.50)	98.50 (76.00–150.75)	50.00 (34.00–118.00)	54.00 (41.00–104.00)	0.037
INR	1.26 (1.16–1.40)	1.27 (1.15–1.38)	1.25 (1.16–1.46)	1.30 (1.21–1.36)	1.25 (1.20–1.64)	0.861
Duration of ICU stay, h	112.00 (68.00–177.50)	115.50 (69.50–185.25)	113.00 (77.75–176.25)	89.00 (43.00–122.00)	83.00 (50.00–112.00)	0.465
Transplant outcomes						0.139
Abandoned	2 (2.3)	0	0	2 (22.2)	0	
PNF	2 (2.3)	0	0	1 (11.1)	1 (20.0)	
EAD	11 (12.5)	4 (9.1)	4 (13.3)	2 (22.2)	1 (20.0)	
Recover successfully	73 (83.0)	40 (90.9)	26 (86.7)	4 (44.4)	3 (60.0)	

Values represent the mean ± standard deviation, median (25th–75th percentiles), or number of patients (%). *, there was a statistically significant difference between the steatosis and non-steatosis groups. HBV, hepatitis B virus; HCV, hepatitis C virus; PSV, peak systolic flow velocity; EDV, end-diastolic velocity; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; ICU, intensive care unit; EAD, early allograft dysfunction; PNF, primary non-function.




Figure S1 Comparison of PIHA (A), PIPV (B), and PILP (C) among hepatic steatosis (HS) grades. PIHA ($P < 0.001$), PIPV ($P < 0.001$), and PILP ($P < 0.001$) were significantly reduced with increasing HS grades. In post hoc analysis with the least significant difference t -test, the severe HS group demonstrated significantly lower PIHA ($P = 0.007$), PIPV ($P < 0.001$), and PILP ($P = 0.01$) than the mild HS group, whereas PIHA ($P < 0.001$) and PIPV ($P < 0.001$) were significantly lower in the moderate HS group than in the mild HS group. PIHA, peak intensity of hepatic artery; PIPV, peak intensity of portal vein; PILP, peak intensity of liver parenchyma.